Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide in chemo-naïve castration-resistant prostate cancer
NCT02814968Phase 2Completed
- Sponsor
- European Uro-Oncology Group
- Start
- Feb 2015
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enzalutamide in castration-resistant prostate cancer (CRPC), sponsored by European Uro-Oncology Group. Started Feb 2015; status: completed.
02
Drugs
enzalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02814968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02814968.